180 Life Sciencesの内部者の所有権

180 Life Sciencesの内部者の所有権は何ですか。

180 Life Sciences Corp.の内部者の所有権は35.33%です。

内部者の所有権の定義は何ですか。



管理の所有権(Insider Ownership)は、発行済株式総数で除したインサイダー(5%超を所有する株主または取締役または役員) が所有する株式総数によって計算されます。

A high value of insider ownership means that those working for the company have a large stake in the success of the company. This is sometimes seen as a sign that those running the company will work hard to ensure its success or believe the company's stock price will rise.

A change in insider ownership may come from exercise of option, stock grant and buying or selling of company shares. A purchase of company share signifies a confidence in the company's future performance by people who know the company best. Therefore, Net Insider buying is also an important indicator for investors.

NASDAQのセクタHealth Careにおける内部者の所有権の企業と比べる180 Life Sciences

180 Life Sciencesは何をしますか。

180 Life Sciences Corp., a clinical-stage biotechnology company, engages in the development of novel drugs for unmet medical needs in chronic pain, inflammation, inflammatory diseases, and fibrosis. Its product development platforms in Phase IIb/III clinical trials include Fibrosis and anti-tumour necrosis factor (Anti-TNF) platform, which focuses on fibrosis and Anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which are man-made derivatives of CBD; and a7nAChR platform, which focuses on alpha 7 nicotinic acetylcholine receptor. The company was incorporated in 2016 and is headquartered in Palo Alto, California.

180 Life Sciencesと類似の内部者の所有権